In addition, 24 patients with FGFR2 fusion mutations were reported in the MSKCC 10,000 sequencing data, including 18 cases of cholangiocarcinoma (242 cases in total), accounting for 75% of all FGFR2 fusion mutations. This evidence concerns the gene FGFR2 and cholangiocarcinoma.